Spring project submission period for promising care subsidy scheme (coverage with evidence development) was opened in the Netherlands

26

Apr 2019

The scheme entered into force on February 1, 2019. It has been published in the Dutch Government Gazette on January 15, 2019. The regulation contains rules for the provision of a subsidy for promising care.

The Dutch National Health Care Institute (Zorginstituut Nederland, ZIN) has opened a project submission period in a framework of subsidy scheme called “Promising care.” This scheme makes it possible to obtain temporary financing for those treatment methods that look promising but are not yet reimbursed from the basic package. If the subsidy is received, the research data regarding the efficacy and cost-effectiveness of the granted treatment method should start being collected. After the end of the project, an assessment will be made by the Healthcare Institute within 6 months to understand whether this treatment method is going to be included in the basic health insurance package. A grant for projects is awarded for a maximum of 6 years.

With this scheme, the Ministry of Health, Welfare and Sport makes a maximum of €69 million available annually. The subsidy ceiling for the 1st round is € 40 million. If the subsidy ceiling is not reached, the remaining amount will be transferred to the 2nd round of the same calendar year. The 2nd round in 2019 is expected to start at the end of June and close at the end of August.

The period for submitting project ideas for promising care is from March 14 to May 14, 2019.

See the full information in Dutch here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

25

Mar 2022

On March 4, 2022, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced three projects which received a subsidy under the "Subsidy scheme for promising care" in 2022 for research of a new minimally invasive endoscopy-guided surgery in patients with spontaneous cerebral hemorrhage, oral immunotherapy in children to cure a food allergy and cutting the diaphragm band in chronic abdominal complaints.

Read more

23

Mar 2022

In late January 2022, Swedish Medical Technologies Product (MTP) Council issued an updated version of recommendations regarding gene expression analysis for decision-making on the adjuvant breast cancer treatment, initially published in November 2021. The recommendation to the regions remains the same. The changes were only concerned with the clarification of some facts.

Read more

21

Mar 2022

The NHS Insights Prioritisation Programme (NIPP) is commissioned by the NHS Accelerated Access Collaborative (AAC) and the National Institute for Health Research (NIHR). It is designed to accelerate the evaluation and implementation of innovation that supports post-pandemic ways of working, builds service resilience, and delivers benefits to patients. Fourteen projects have been funded and have now commenced activity that will be ongoing until March 2023.

Read more

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

16

Mar 2022

In February 2022, Swedish Medical Technologies Product (MTP) Council issued an updated recommendation on FreeStyle Libre for continuous glucose monitoring in type 2 diabetes (T2D). The initial recommendations were published by NT Council in 2018 and updated by MTP Council in 2020 to include FreeStyle Libre 2. In the 2022 update, MTP Council decreased the Hba1c limit from 70 to 60 mmol/mol and added a statement on lifestyle changes and treatment optimization with non-insulin antidiabetic drugs.

Read more